Rapporto sull’analisi delle dimensioni e delle quote del mercato della difesa biologica | Previsioni 2031

  • Report Code : TIPRE00005377
  • Category : Biotechnology
  • Status : Published
  • No. of Pages : 136
Buy Now

Il mercato della difesa biologica dovrebbe raggiungere 8.350,74 milioni di dollari nel 2027 da 4.108,24 milioni di dollari nel 2019. Si stima che il mercato crescerà con un CAGR del 9,4% dal 2020 al 2027.< /h3>

La biodefesa si riferisce alle misure adottate per ripristinare la biosicurezza di un gruppo di organismi che sono, o possono essere, soggetti a minacce biologiche o malattie infettive. Si tratta di un sistema sanitario pubblico efficace con una forte sorveglianza delle malattie e azioni rapide progettate per contrastare le minacce biologiche, limitare la diffusione delle malattie e fornire assistenza medica urgente. La crescita del mercato è attribuita ad alcuni fattori chiave come la presenza di iniziative governative favorevoli, l’aumento del numero di epidemie naturali, la crescente minaccia delle armi biologiche e dei missili balistici intercontinentali armati nucleari. Tuttavia, si prevede che i bassi finanziamenti per ricerca e sviluppo da parte del governo nelle economie in via di sviluppo e sottosviluppate limiteranno la crescita del mercato della biodifesa durante gli anni previsti.

Mercati regionali redditizi della difesa biologica



Approfondimenti di mercato

Presenza di iniziative governative favorevoli

< p>Ogni anno, il governo investe molto nella ricerca e sviluppo dei vaccini per rimanere preparato a eventuali attacchi bioterroristici. Ad esempio, nel 2018, il governo degli Stati Uniti ha pubblicato la strategia nazionale e il piano di attuazione della difesa biologica, la strategia di sicurezza nazionale, la strategia di difesa nazionale, la strategia nazionale antiterrorismo e la strategia nazionale contro le armi di distruzione di massa, che includono tutte la biosicurezza e la biodifesa. Inoltre, il governo degli Stati Uniti si sta preparando per la Strategia di sicurezza sanitaria globale e sta sostenendo lo sviluppo di un quadro 2024 dell’Agenda di sicurezza sanitaria globale, che prevede la prevenzione, l’individuazione e la risposta alle minacce biologiche naturali, accidentali e intenzionali.

Potenzia i vaccini antinfluenzali e la sicurezza sanitaria è il bilancio che sostiene l'Ordine esecutivo 13887, "Modernizzare i vaccini antinfluenzali negli Stati Uniti per promuovere la sicurezza nazionale e la salute pubblica", prevedendo un aumento di 95 milioni di dollari, rispetto al livello emanato nel 2020, per i servizi sanitari e umani (HHS) per le infrastrutture e l’innovazione per la produzione di vaccini antinfluenzali; ricerca avanzata e sviluppo di vaccini, terapie e strumenti diagnostici migliorati; preparazione alla pandemia internazionale; e una migliore copertura vaccinale a livello nazionale. Il Bilancio finanzia anche la biodifesa dell’HHS e gli appalti per la preparazione alle emergenze attraverso il programma BioShield e le scorte nazionali strategiche. Comprende 175 milioni di dollari a sostegno delle attività di sicurezza sanitaria globale del CDC, con un aumento di 50 milioni di dollari rispetto al livello emanato nel 2020.

Mentre il governo si impegna in queste attività attuali e future attività politiche, comprendendo la politica esistente di biosicurezza e di biodifesa, le aziende farmaceutiche che operano nel mercato della biodifesa hanno notevoli opportunità di espandersi ed essere preparate a qualsiasi bioterrorismo. Ad esempio, lo sviluppatore di antibiotici Spero Therapeutics ha ricevuto 15,7 milioni di dollari in finanziamenti per la ricerca federale dalla Biomedical Advanced Research and Development Authority per il suo candidato orale della classe dei carbapenemi, SPR994, per valutare l'efficacia del farmaco contro le minacce biologiche, tra cui antrace, peste e melioidosi. Inoltre, l'Autorità per la ricerca e lo sviluppo avanzato biomedico prevede anche accantonamenti per un massimo di ulteriori 28,5 milioni di dollari in cinque anni e sosterrà anche lo sviluppo clinico di Spero di SPR994 nelle infezioni complicate del tratto urinario causate da batteri resistenti ai farmaci. Le iniziative dei governi di tutto il mondo aprono una finestra di opportunità per le aziende coinvolte nel settore della biodifesa.

Approfondimenti sul prodotto

Il mercato della biodifesa, per prodotto , è segmentato in antrace, vaiolo, botulismo, radiazioni/nucleare e altri. Nel 2019, il segmento dell’antrace rappresentava la quota di mercato maggiore nel mercato globale della biodifesa. Si prevede che il segmento continuerà a dominare nel periodo di previsione grazie ai crescenti finanziamenti da parte dei governi di altri paesi per sviluppare e accumulare vaccini adeguati contro l’antrace, principalmente attraverso una serie di iniziative, come BioShield Act, Biomedical Advanced Research and Development Authority (BARDA ) e l'ufficio esecutivo del programma congiunto per le attività chimiche e biologiche. Difesa biologica.

Mercato globale della difesa biologica, per prodotto - 2018 e 2027



Approfondimenti strategici

La strategia di lancio e approvazione dei prodotti è comunemente adottata dalle aziende per espandere la propria presenza in tutto il mondo e soddisfare la crescente domanda. Questa strategia è più comunemente adottata dagli operatori del mercato al fine di espandere il proprio portafoglio di prodotti.

Gli operatori del mercato che operano nel mercato della biodifesa adottano la strategia di espansione per ampliare la base di clienti in tutto il mondo, il che consente anche ai giocatori di mantenere il proprio marchio a livello globale. Ad esempio, nel gennaio 2017, Emergent BioSolutions Inc. ha ricevuto l'approvazione del Ministero federale della sanità tedesco per commercializzare BioThrax (vaccino adsorbito contro l'antrace) prodotto nell'edificio 55 in Germania.

Mercato globale della biodifesa: Per prodotto

  • Antrace
  • Vaiolo
  • Botulismo
  • Radiazioni/Nucleare
  • Altro

Mercato della biodifesa: Per area geografica

  • Nord America
    • Stati Uniti
    • Canada
    • Messico
  • < li>Europa
    • Francia
    • Germania
    • Italia
    • Regno Unito
    • Spagna
    • Resto dell'Europa
  • Asia Pacifico
    • Cina
    • India
    • Corea del Sud
    • Giappone
    • Australia
    • Resto dell'Asia Pacifico
  • Medio Oriente e Stati Uniti. Africa
    • Sudafrica
    • Arabia Saudita
    • Emirati Arabi Uniti
    • Resto del Medio Oriente e dell'Africa
  • Sudamerica
    • Brasile
    • Argentina
    • Resto del Sudamerica

Profili aziendali

  • Bavarese nordico
  • Alnylam Pharmaceuticals, Inc.
  • SIGA Technologies
  • < li>Emergent BioSolutions Inc.
  • Cleveland Bio Labs
  • Dynavax Technologies
  • Elusys Therapeutics, Inc.
  • Soligenix
  • < li>Altimmune
  • Pluristem Therapeutics
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


What is biodefense?

Biodefense is referred to the measures taken to restore biosecurity of a group of organism that are, or may be, subject to biological threats or infectious diseases. It is an effective public health care system with strong disease surveillance and rapid actions designed to counter biological threats, to limit the spread of disease and provide surge medical care.

What are the driving factors for the bioresorbable medical materials market across the globe?

Driving factors such as presence of favorable government initiatives increase in the number of naturally occurring outbreaks, increasing threat of biological weapons and nuclear armed ICBM. Additionally, the future trend such as predictive analytics to reshape biodefense market is likely to increase the growth in the forecast period.

What is the regional analysis in terms of bioresorbable medical materials?

Global biodefense market is segmented by region into North America, Europe, Asia Pacific, Middle East & Africa and South & Central America. In North America, the U.S. is the largest market for biodefense. Biological threats occurring to humans, animals and environment are among the most serious issues faced by the US and its national community. As the biological threat continues to increase, the US is focused towards strengthening its capabilities and considering preparation for bio threats and bioterrorism as one of the critical aspects of national security. The federal government in the US coordinates programs, and sets up budgets so as to prevent, respond and take actions against biological disasters.

The List of Companies - Biodefense Market

  1. Bavarian Nordic
  2. Alnylam Pharmaceuticals, Inc.
  3. SIGA Technologies
  4. Emergent BioSolutions Inc.
  5. Cleveland Bio Labs
  6. Dynavax Technologies
  7. Elusys Therapeutics, Inc.
  8. Soligenix
  9. Altimmune
  10. Pluristem Therapeutics

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports